Quinomycin C

Details

• Internal ID: 23a66f85-cc7a-4e24-a2fa-2d7d07a84be9
• Taxonomy: Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides
• IUPAC Name: N-[2,4,12,15,17,25-hexamethyl-27-methylsulfanyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-20-(quinoxaline-2-carbonylamino)-9,22-dioxa-28-thia-2,5,12,15,18,25-hexazabicyclo[12.12.3]nonacosan-7-yl]quinoxaline-2-carboxamide
• InChI: InChI=1S/C51H64N12O12S2/c1-25(2)38-49(72)74-22-36(59-42(65)34-21-53-30-17-13-15-19-32(30)57-34)44(67)55-28(6)46(69)63(10)40-48(71)62(9)39(26(3)4)50(73)75-23-35(58-41(64)33-20-52-29-16-12-14-18-31(29)56-33)43(66)54-27(5)45(68)60(7)37(47(70)61(38)8)24-77-51(40)76-11/h12-21,25-28,35-40,51H,22-24H2,1-11H3,(H,54,66)(H,55,67)(H,58,64)(H,59,65)
• InChI Key: AUJXLBOHYWTPFV-UHFFFAOYSA-N
• Popularity: 104 references in papers

Physical and Chemical Properties

• Molecular Formula: C₅₁H₆₄N₁₂O₁₂S₂
• Molecular Weight: 1101.30 g/mol
• Exact Mass: 1100.42080787 g/mol
• Topological Polar Surface Area (TPSA): 352.00 Ų
• XlogP: 2.70
• Atomic LogP (AlogP): 0.64
• H-Bond Acceptor: 18
• H-Bond Donor: 4
• Rotatable Bonds: 7

Synonyms

• Levomycin
• Quinomycin A
• 512-64-1
• NSC526417
• MLS002702903
• 1403-88-9
• Quinomycin A;NSC-13502
• S-426-S (Lepetit)
• NSC-526417
• SMR001566720
• Echinomycin A
• N,N'-(11,24-diisopropyl-2,4,12,15,17,25-hexamethyl-27-(methylthio)-3,6,10,13,16,19,23,26-octaoxo-9,22-dioxa-28-thia-2,5,12,15,18,25-hexaazabicyclo[12.12.3]nonacosane-7,20-diyl)bis(quinoxaline-2-carboxamide)
• GNF-PF-1958
• NSC-13502
• N-[2,4,12,15,17,25-hexamethyl-27-methylsulfanyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-20-(quinoxaline-2-carbonylamino)-9,22-dioxa-28-thia-2,5,12,15,18,25-hexazabicyclo[12.12.3]nonacosan-7-yl]quinoxaline-2-carboxamide
• Quinomycin A (7CI,
• cid_3197
• Neuro_000224
• SCHEMBL63091
• Echinomycin (NSC-13502)
• CHEMBL263730
• DTXSID5031266
• BDBM93922
• Antibiotic C638-8, crystalline
• NSC13502
• AKOS040741684
• echinomycin (undefined stereochemistry)
• C 6388
• Levomycin; Echinomycin; Quinomycin A; NSC526417
• Q5332566
• 2-Quinoxalinecarboxmide,N'-[2,4,12,15,17,25-hexamethyl-~ 11,24-bis(1-methylethyl)-27-(methylthio)-3,6,10,13,16,19,23~ ,26-octaoxo-9,22-dioxa-28-thia-2,5,12,15,18,25-hexaazabicyclo [12.12.3]nonacosane-7,20-diyl]bis-
• 2-Quinoxalinecarboxmide,N'-[2,4,12,15,17,25-hexamethyl-11,24-bis(1-methylethyl) -27-(methylthio)-3,6,10,13,16,19,23,26-octaoxo-9,22-dioxa -28-thia-2,5,12,15,18,25-hexaazabicyclo[12.12.3]nonacosan e-7,20-diyl]bis-
• WLN: T C-16-6-16-/CE& A B C- C- 2CP E& AS CX C-S DNV GMV KOV NNV PXNV TMV A&OV D&NVTJ D1

2D Structure

ADMET Properties (via admetSAR 2)

Target	Value	Probability (raw)	Probability (%)
Human Intestinal Absorption	+	0.6328	63.28%
Caco-2	-	0.8583	85.83%
Blood Brain Barrier	-	0.8500	85.00%
Human oral bioavailability	-	0.6714	67.14%
Subcellular localzation	Lysosomes	0.4989	49.89%
OATP2B1 inhibitior	-	0.7102	71.02%
OATP1B1 inhibitior	+	0.8562	85.62%
OATP1B3 inhibitior	+	0.9318	93.18%
MATE1 inhibitior	-	0.8000	80.00%
OCT2 inhibitior	-	1.0000	100.00%
BSEP inhibitior	+	0.8412	84.12%
P-glycoprotein inhibitior	+	0.7533	75.33%
P-glycoprotein substrate	+	0.7745	77.45%
CYP3A4 substrate	+	0.7063	70.63%
CYP2C9 substrate	-	0.5692	56.92%
CYP2D6 substrate	-	0.8754	87.54%
CYP3A4 inhibition	-	0.5870	58.70%
CYP2C9 inhibition	-	0.7322	73.22%
CYP2C19 inhibition	-	0.7210	72.10%
CYP2D6 inhibition	-	0.8619	86.19%
CYP1A2 inhibition	-	0.6776	67.76%
CYP2C8 inhibition	+	0.6712	67.12%
CYP inhibitory promiscuity	-	0.9011	90.11%
UGT catelyzed	-	0.0000	0.00%
Carcinogenicity (binary)	-	0.8000	80.00%
Carcinogenicity (trinary)	Non-required	0.6248	62.48%
Eye corrosion	-	0.9858	98.58%
Eye irritation	-	0.9001	90.01%
Skin irritation	-	0.7722	77.22%
Skin corrosion	-	0.9322	93.22%
Ames mutagenesis	-	0.6200	62.00%
Human Ether-a-go-go-Related Gene inhibition	+	0.8050	80.50%
Micronuclear	+	0.7800	78.00%
Hepatotoxicity	+	0.6000	60.00%
skin sensitisation	-	0.8566	85.66%
Respiratory toxicity	+	0.8667	86.67%
Reproductive toxicity	+	0.8000	80.00%
Mitochondrial toxicity	+	0.9337	93.37%
Nephrotoxicity	-	0.7095	70.95%
Acute Oral Toxicity (c)	III	0.6094	60.94%
Estrogen receptor binding	+	0.7981	79.81%
Androgen receptor binding	+	0.7616	76.16%
Thyroid receptor binding	+	0.6466	64.66%
Glucocorticoid receptor binding	+	0.7060	70.60%
Aromatase binding	+	0.6809	68.09%
PPAR gamma	+	0.8101	81.01%
Honey bee toxicity	-	0.7916	79.16%
Biodegradation	-	0.8500	85.00%
Crustacea aquatic toxicity	-	0.5047	50.47%
Fish aquatic toxicity	+	0.9303	93.03%

Targets

Proven Targets:

No proven targets yet!

Predicted Targets (via Super-PRED):

CHEMBL ID	UniProt ID	Name	Probability	Model accuracy
CHEMBL3251	P19838	Nuclear factor NF-kappa-B p105 subunit	98.60%	96.09%
CHEMBL4261	Q16665	Hypoxia-inducible factor 1 alpha	97.62%	85.14%
CHEMBL3038477	P67870	Casein kinase II alpha/beta	96.13%	99.23%
CHEMBL2107	P61073	C-X-C chemokine receptor type 4	94.35%	93.10%
CHEMBL2581	P07339	Cathepsin D	92.69%	98.95%
CHEMBL1293277	O15118	Niemann-Pick C1 protein	91.79%	81.11%
CHEMBL3108638	O15164	Transcription intermediary factor 1-alpha	91.60%	95.56%
CHEMBL2492	P36544	Neuronal acetylcholine receptor protein alpha-7 subunit	90.61%	88.42%
CHEMBL4208	P20618	Proteasome component C5	86.99%	90.00%
CHEMBL2335	P42785	Lysosomal Pro-X carboxypeptidase	85.45%	100.00%
CHEMBL5845	P23415	Glycine receptor subunit alpha-1	84.76%	90.71%
CHEMBL2693	Q9UIQ6	Cystinyl aminopeptidase	84.72%	97.64%
CHEMBL5619	P27695	DNA-(apurinic or apyrimidinic site) lyase	83.51%	91.11%
CHEMBL1806	P11388	DNA topoisomerase II alpha	83.33%	89.00%
CHEMBL3310	Q96DB2	Histone deacetylase 11	83.10%	88.56%
CHEMBL5028	O14672	ADAM10	82.38%	97.50%
CHEMBL1907598	P05106	Integrin alpha-V/beta-3	82.12%	95.71%
CHEMBL3267	P48736	PI3-kinase p110-gamma subunit	82.12%	95.71%
CHEMBL1795139	Q8IU80	Transmembrane protease serine 6	81.46%	98.33%
CHEMBL2535	P11166	Glucose transporter	81.10%	98.75%

Plants that contains it

There are no matching plants.

Cross-Links

• PubChem: 3197
• LOTUS: LTS0205936
• wikiData: Q5332566